Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04640428
  4. Details
NCT04640428 Clinical Trial

COVID-19 Stroke Apical Lung Examination Study

Covid19 Clinical Trial

Official title:
COVID-19 Stroke Apical Lung Examination Study - A Multi-centre Prospective Study

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04640428
Other study ID # COVID SALES 2
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 10, 2020
Est. completion date October 31, 2021

Study information
Verified date May 2021
Source King's College Hospital NHS Trust
Contact Nathan Chan, FRCR
Phone +44(0)7508192126
Email covidsalesresearch@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Multi-centre prospective study evaluating computed tomography angiography studies performed for stroke patients as a diagnostic and prognostic imaging biomarker.

Description:

Diagnosis of coronavirus disease 2019 (COVID-19) relies on clinical features and reverse-transcriptase polymerase chain reaction (RT-PCR) testing. The latter is constrained by limited sensitivity and a timescale of hours to yield results, with no point-of-care test widely available. A dedicated computed tomography study of the chest is likely to be more sensitive than RT-PCR for COVID-19. Carotid computed tomography angiography (CTA) is a routine acute stroke investigation and includes the lung apices. We aim to assess the lung apices on CTA for ground glass opacification and compare this with COVID-19 RT-PCR test results and clinical outcome measures.

Recruitment information / eligibility
Status Recruiting
Enrollment 2000
Est. completion date October 31, 2021
Est. primary completion date October 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: All adult patients presenting with clinical features of acute ischaemic stroke undergoing investigation with computed tomography angiography at presentation. Exclusion Criteria: Poor image quality. No radiologist report available. Computed tomography angiography performed in a non-acute setting.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
United Kingdom Royal United Hospitals Bath NHS Foundation Trust Bath
United Kingdom North Bristol NHS Trust Bristol
United Kingdom University Hospitals Bristol NHS Foundation Trust Bristol
United Kingdom Frimley Health NHS Foundation Trust Camberley
United Kingdom Cardiff and Vale University Health Board Cardiff
United Kingdom University Hospitals Coventry and Warwickshire NHS Trust Coventry
United Kingdom Leeds Teaching Hospitals NHS Trust Leeds
United Kingdom Guy's and St Thomas' NHS Foundation Trust London
United Kingdom Imperial College Healthcare NHS Foundation Trust London
United Kingdom King's College Hospital NHS FT (KCH) London
United Kingdom King's College Hospital NHS FT (PRUH) London
United Kingdom University College London NHS Foundation Trust London

Sponsors (2)
Lead Sponsor Collaborator
King's College Hospital NHS Trust National Institute for Health Research, United Kingdom

Country where clinical trial is conducted

United Kingdom, 

Outcome
Type Measure Description Time frame Safety issue
Primary Accuracy of the computed tomography angiography biomarker relative to the COVID-19 RT-PCR test Defined by sensitivity, specificity, positive and negative predictive values 1 month
Secondary Prognostic value of the computed tomography biomarker Defined by its relationship with 30 day mortality and modified rankin scale following treatment 1 month
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3